Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
AbCellera (Nasdaq: ABCL) announced a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera will use its proprietary TCE platform to lead discovery and early development activities, while Vertex will fund all research and development costs and hold the rights to develop and commercialize resulting multispecific antibodies.
According to AbCellera, it will receive $28 million in total upfront payments and may earn additional preclinical, development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. The companies may also mutually agree for AbCellera to conduct cell line development, process development, and clinical manufacturing through Phase 1 for collaboration programs.
Vertex (Nasdaq:VRTX) will report its Q2 2026 financial results on Monday, August 3, 2026, after market close. A conference call and live webcast are scheduled for 4:30 p.m. ET, accessible via phone or through the Investors section of the company website.
Vertex (Nasdaq: VRTX) will acquire Crinetics (Nasdaq: CRNX) for $85 per share in cash, implying equity value of about $10 billion, or $8.8 billion net of cash. The deal, unanimously approved by both boards, is expected to close in Q3 2026.
The acquisition adds commercial acromegaly drug PALSONIFY and Phase 3 CAH candidate atumelnant. Vertex expects immediate revenue contribution from PALSONIFY, combined peak annual revenue of >$5 billion, and accretion to non-GAAP operating income in 2029. Financing will use cash plus debt, including $4.5 billion in committed bridge funding.
Vertex (Nasdaq: VRTX) received US FDA approval to expand use of CASGEVY (exagamglogene autotemcel) to people ages 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
CASGEVY is the first approved genetic therapy for these conditions in children as young as 2, making approximately 5,500 additional US children eligible. Vertex reports more than 75 authorized treatment centers are activated in the US, and regulatory review for label expansion is underway in the Kingdom of Saudi Arabia and the United Kingdom.
Vertex (Nasdaq: VRTX) reported new Phase 3 data on CASGEVY in children ages 5–11 with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).
All evaluable SCD patients (8/8) were VOC-free ≥12 months, and all evaluable TDT patients (8/8) achieved ≥12 months transfusion independence, supporting ongoing global regulatory submissions for younger children.
Vertex (Nasdaq: VRTX) presented new Phase 3 and long-term data for ALYFTREK and TRIKAFTA in young children with cystic fibrosis at the European Cystic Fibrosis Conference.
Key results include large reductions in sweat chloride, 96‑week safety data in patients ≥6, and plans for global regulatory submissions starting in 2026.
Vertex (Nasdaq: VRTX) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. President and CEO Dr. Reshma Kewalramani will join a fireside chat on June 10, 2026, at 11:20 a.m. ET.
A live and archived webcast will be available in the Investors section of the Vertex website.
Vertex (Nasdaq: VRTX) announced FDA acceptance of its Biologics License Application for povetacicept in adults with IgA nephropathy, with a PDUFA target action date of November 30, 2026.
The Phase 3 RAINIER trial met primary and secondary endpoints, showing large reductions in proteinuria, Gd-IgA1 and hematuria, with a generally favorable safety profile.
Vertex (Nasdaq: VRTX) announced executive participation in two May 2026 investor conferences. Chief Operating and Financial Officer Charlie Wagner will join a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026, at 2:35 p.m. ET.
Chief Executive Officer and President Dr. Reshma Kewalramani will participate in a fireside chat at Bernstein’s 42nd Annual Strategic Decisions Conference on May 29, 2026, at 9:00 a.m. ET.
Vertex (NASDAQ: VRTX) signed a reimbursement agreement with the GKV-Spitzenverband to secure sustainable access in Germany for CASGEVY (exagamglogene autotemcel), a one-time CRISPR/Cas9 gene-edited therapy for eligible patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia.
Germany joins multiple countries with reimbursement coverage for CASGEVY as Vertex continues working with payers to expand sustainable patient access.